Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients

Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon discontinuing treatment. However, the underlying mechanisms of this phenomenon remain incompletely understood. This study aims to elucidate the me...

Full description

Saved in:
Bibliographic Details
Published inNPJ systems biology and applications Vol. 10; no. 1; p. 45
Main Authors Lai, Xiulan, Jiao, Xiaopei, Zhang, Haojian, Lei, Jinzhi
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 27.04.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon discontinuing treatment. However, the underlying mechanisms of this phenomenon remain incompletely understood. This study aims to elucidate the mechanism of TFR in CML patients, focusing on the feedback interaction between leukemia stem cells and the bone marrow microenvironment. We have developed a mathematical model to explore the interplay between leukemia stem cells and the bone marrow microenvironment, allowing for the simulation of CML progression dynamics. Our proposed model reveals a dichotomous response following TKI discontinuation, with two distinct patient groups emerging: one prone to early molecular relapse and the other capable of achieving long-term TFR after treatment cessation. This finding aligns with clinical observations and underscores the essential role of feedback interaction between leukemic cells and the tumor microenvironment in sustaining TFR. Notably, we have shown that the ratio of leukemia cells in peripheral blood (PBLC) and the tumor microenvironment (TME) index can be a valuable predictive tool for identifying patients likely to achieve TFR after discontinuing treatment. This study provides fresh insights into the mechanism of TFR in CML patients and underscores the significance of microenvironmental control in achieving TFR.
AbstractList Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon discontinuing treatment. However, the underlying mechanisms of this phenomenon remain incompletely understood. This study aims to elucidate the mechanism of TFR in CML patients, focusing on the feedback interaction between leukemia stem cells and the bone marrow microenvironment. We have developed a mathematical model to explore the interplay between leukemia stem cells and the bone marrow microenvironment, allowing for the simulation of CML progression dynamics. Our proposed model reveals a dichotomous response following TKI discontinuation, with two distinct patient groups emerging: one prone to early molecular relapse and the other capable of achieving long-term TFR after treatment cessation. This finding aligns with clinical observations and underscores the essential role of feedback interaction between leukemic cells and the tumor microenvironment in sustaining TFR. Notably, we have shown that the ratio of leukemia cells in peripheral blood (PBLC) and the tumor microenvironment (TME) index can be a valuable predictive tool for identifying patients likely to achieve TFR after discontinuing treatment. This study provides fresh insights into the mechanism of TFR in CML patients and underscores the significance of microenvironmental control in achieving TFR.
Abstract Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon discontinuing treatment. However, the underlying mechanisms of this phenomenon remain incompletely understood. This study aims to elucidate the mechanism of TFR in CML patients, focusing on the feedback interaction between leukemia stem cells and the bone marrow microenvironment. We have developed a mathematical model to explore the interplay between leukemia stem cells and the bone marrow microenvironment, allowing for the simulation of CML progression dynamics. Our proposed model reveals a dichotomous response following TKI discontinuation, with two distinct patient groups emerging: one prone to early molecular relapse and the other capable of achieving long-term TFR after treatment cessation. This finding aligns with clinical observations and underscores the essential role of feedback interaction between leukemic cells and the tumor microenvironment in sustaining TFR. Notably, we have shown that the ratio of leukemia cells in peripheral blood (PBLC) and the tumor microenvironment (TME) index can be a valuable predictive tool for identifying patients likely to achieve TFR after discontinuing treatment. This study provides fresh insights into the mechanism of TFR in CML patients and underscores the significance of microenvironmental control in achieving TFR.
Abstract Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon discontinuing treatment. However, the underlying mechanisms of this phenomenon remain incompletely understood. This study aims to elucidate the mechanism of TFR in CML patients, focusing on the feedback interaction between leukemia stem cells and the bone marrow microenvironment. We have developed a mathematical model to explore the interplay between leukemia stem cells and the bone marrow microenvironment, allowing for the simulation of CML progression dynamics. Our proposed model reveals a dichotomous response following TKI discontinuation, with two distinct patient groups emerging: one prone to early molecular relapse and the other capable of achieving long-term TFR after treatment cessation. This finding aligns with clinical observations and underscores the essential role of feedback interaction between leukemic cells and the tumor microenvironment in sustaining TFR. Notably, we have shown that the ratio of leukemia cells in peripheral blood (PBLC) and the tumor microenvironment (TME) index can be a valuable predictive tool for identifying patients likely to achieve TFR after discontinuing treatment. This study provides fresh insights into the mechanism of TFR in CML patients and underscores the significance of microenvironmental control in achieving TFR.
ArticleNumber 45
Author Lai, Xiulan
Zhang, Haojian
Jiao, Xiaopei
Lei, Jinzhi
Author_xml – sequence: 1
  givenname: Xiulan
  surname: Lai
  fullname: Lai, Xiulan
  organization: Institute for Mathematical Sciences, Renmin University of China
– sequence: 2
  givenname: Xiaopei
  surname: Jiao
  fullname: Jiao, Xiaopei
  organization: Department of Mathematics, Tsinghua University
– sequence: 3
  givenname: Haojian
  orcidid: 0000-0002-9394-9383
  surname: Zhang
  fullname: Zhang, Haojian
  email: Haojian_Zhang@whu.edu.cn
  organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Medical Research Institute, School of Medicine, Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University
– sequence: 4
  givenname: Jinzhi
  orcidid: 0000-0002-2670-6760
  surname: Lei
  fullname: Lei, Jinzhi
  email: jzlei@tiangong.edu.cn
  organization: School of Mathematical Sciences, Center for Applied Mathematics, Tiangong University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38678088$$D View this record in MEDLINE/PubMed
BookMark eNp9Uktv1DAQjlARLaV_gAOKxIVLYGI7tnNCaAW0UiUucLYce7z1NomDnay0_x5vU_rgwMn2fI_x2N_r4mQMIxbF2xo-1kDlp8TqhkEFhFUAVEDFXhRnBBpeiVq2J0_2p8VFSjsAqDllpIZXxSmVXEiQ8qyYNmGYllnPPoy6L4dgsffjtoy4R92n8hYPpdNmDjGVNvr9EZsj6nnAca5cRMzUwaeU9aUfS3MTw-hNORywD96WPS63GdfllFtkSXpTvHTZGC_u1_Pi17evPzeX1fWP71ebL9eVYSBYRbUVnLFGWtrZXKEdcmyJEBw7ZywjHWvzmYvWEacFbTq0LWdtqwUhwhl6XlytvjbonZqiH3Q8qKC9uiuEuFU6zt70qDoN1nGn0QAybaQmUlvAjkjWOcbb7PV59ZqWbkBr8hxR989MnyOjv1HbsFd1DU0jJWSHD_cOMfxeMM0qv5nBvtcjhiUpCky0jDZwpL7_h7oLS8yfs7IYsKbhmUVWlokhpYju4TY1qGNA1BoQlQOi7gKiWBa9ezrHg-RvHDKBroSUoXGL8bH3f2z_AOe9yxI
Cites_doi 10.1158/0008-5472.CAN-15-0611
10.1046/j.1365-2184.2001.00195.x
10.1182/blood-2011-02-339267
10.1371/journal.pcbi.1005803
10.1038/nm1487
10.1182/blood-2016-09-696013
10.1038/s41375-021-01238-w
10.1007/s00432-018-2604-x
10.1158/0008-5472.CAN-19-2175
10.3324/haematol.2018.194522
10.1056/NEJM200104053441401
10.1038/s41568-020-0245-2
10.1016/S0022-5193(03)00090-0
10.1016/j.retram.2021.103295
10.1200/JCO.2016.68.2914
10.1038/leu.2016.360
10.1038/nm.3364
10.1093/stmcls/sxac079
10.1038/s41598-018-21115-4
10.1111/bjh.16718
10.1038/s41571-020-0367-1
10.1073/pnas.1317072111
10.1038/s41375-020-0776-2
10.7326/M17-1094
10.1016/j.neo.2022.100817
10.1038/leu.2010.197
10.1056/NEJM198810133191506
10.1016/j.ejca.2017.02.028
10.1016/j.ccr.2010.03.011
10.3324/haematol.2018.197004
10.1182/blood-2017-12-784132
10.1038/leu.2015.36
10.1016/j.clml.2022.09.004
10.3389/fonc.2022.1028871
10.1007/s11899-019-00548-2
10.1182/blood-2013-02-483750
10.1182/blood-2011-08-358135
10.1179/1607845413Y.0000000111
10.1002/cncr.30885
10.1007/s00277-021-04606-9
10.1002/hon.2896
10.1016/j.jtbi.2020.110196
10.1158/0008-5472.CAN-20-0283
10.3389/fonc.2018.00194
10.1182/blood-2013-05-501569
10.3324/haematol.2016.142877
10.1007/s00277-019-03706-x
10.1056/NEJMoa1002315
10.1093/jnci/djr060
10.1016/S1470-2045(18)30192-X
10.1056/NEJMoa062867
10.1016/S1470-2045(10)70233-3
10.1016/S2352-3026(15)00196-9
10.1080/10428194.2019.1675879
10.1097/MOH.0000000000000630
10.1038/s41375-018-0264-0
10.1371/journal.pone.0183620
10.1038/nature03669
10.1111/j.1365-2141.2011.08939.x
10.1073/pnas.0510423103
10.1038/srep24057
10.1056/NEJMoa1609324
10.1038/306277a0
10.1007/s12185-017-2334-x
10.1016/j.jtbi.2018.12.029
10.3109/10428194.2013.831092
10.3390/cells10010117
10.1371/journal.pone.0179700
10.3324/haematol.2015.139899
10.1016/j.mbs.2020.108372
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41540-024-00370-4
DatabaseName Springer Nature OA Free Journals
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Complete (ProQuest Database)
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

CrossRef
MEDLINE - Academic

Publicly Available Content Database

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2056-7189
EndPage 45
ExternalDocumentID oai_doaj_org_article_ba0df6faec0e4ac8a28ad0eb284bf469
10_1038_s41540_024_00370_4
38678088
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)
  grantid: 12171478
  funderid: 501100011002
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 11831015
  funderid: 501100001809
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 12331018
  funderid: 501100001809
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 11831015
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 12331018
– fundername: National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)
  grantid: 12171478
GroupedDBID 0R~
3V.
5VS
7X7
8FE
8FH
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
EBLON
EBS
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
KQ8
LK8
M7P
M~E
NAO
NO~
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
7X8
AFGXO
5PM
ID FETCH-LOGICAL-c4074-3ad764458d3bd4073be6e92776ebfcd42b49e92679f2fa735bed96499a7227fc3
IEDL.DBID RPM
ISSN 2056-7189
IngestDate Fri Oct 04 13:11:02 EDT 2024
Tue Sep 17 21:28:16 EDT 2024
Sat Aug 17 05:21:05 EDT 2024
Thu Oct 10 16:14:13 EDT 2024
Fri Aug 23 02:03:45 EDT 2024
Sun Oct 13 10:15:01 EDT 2024
Fri Oct 11 20:45:15 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4074-3ad764458d3bd4073be6e92776ebfcd42b49e92679f2fa735bed96499a7227fc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9394-9383
0000-0002-2670-6760
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055880/
PMID 38678088
PQID 3047404556
PQPubID 2041915
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_ba0df6faec0e4ac8a28ad0eb284bf469
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11055880
proquest_miscellaneous_3047943500
proquest_journals_3047404556
crossref_primary_10_1038_s41540_024_00370_4
pubmed_primary_38678088
springer_journals_10_1038_s41540_024_00370_4
PublicationCentury 2000
PublicationDate 4-27-2024
PublicationDateYYYYMMDD 2024-04-27
PublicationDate_xml – month: 04
  year: 2024
  text: 4-27-2024
  day: 27
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle NPJ systems biology and applications
PublicationTitleAbbrev npj Syst Biol Appl
PublicationTitleAlternate NPJ Syst Biol Appl
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Mahon (CR17) 2010; 11
Ross (CR21) 2018; 32
Hähnel (CR53) 2020; 80
Campiotti (CR16) 2017; 77
Ashcroft, Manz, Bonhoeffer (CR51) 2017; 13
Radich (CR59) 2006; 103
Molica (CR11) 2019; 98
Chinese Society of Hematology (CR57) 2020; 41
Etienne (CR20) 2016; 35
Gambacorti-Passerini (CR13) 2011; 103
Takahashi (CR29) 2018; 107
Kantarjian (CR8) 2010; 362
Fassoni, Baldow, Roeder, Glauche (CR41) 2018; 103
Ross, Hughes, Melo (CR66) 2011; 25
Druker (CR5) 2006; 355
Clark (CR14) 2019; 14
Ilander (CR33) 2017; 31
Lei (CR70) 2020; 492
Kantarjian (CR60) 2012; 119
Harrington, Lavallade (CR6) 2021; 28
Irani (CR34) 2020; 191
Holyoake, Vetrie (CR4) 2017; 129
Zhang (CR36) 2010; 17
Kurzrock, Gutterman, Talpaz (CR3) 1988; 319
MacLean, Filippi, Stumpf (CR45) 2014; 111
Michor (CR46) 2005; 435
Clapp (CR72) 2015; 75
Duarte, Hawkins, Lo Celso (CR37) 2018; 131
Mackey (CR71) 2001; 34
Ross (CR24) 2018; 144
Brehme (CR58) 2016; 6
Andersen, Hasselbalch, Kjar, Skov, Ottesen (CR43) 2020; 326
Kong (CR35) 2021; 100
Saussele (CR18) 2018; 19
Woywod, Gruber, Engh, Fla (CR42) 2017; 12
Ross (CR19) 2013; 122
Hehlmann (CR62) 2016; 101
Hochhaus (CR12) 2017; 376
Benjamini (CR31) 2014; 55
Minciacchi, Kumar, Krause (CR26) 2021; 10
Andersen (CR39) 2017; 12
Bernard, Bélair, Mackey (CR69) 2003; 223
Stiehl, Wang, Lutz, Marciniak-Czochra (CR48) 2020; 80
Ross, Hughes (CR15) 2020; 17
Azizidoost, Babashah, Rahim, Shahjahani, Saki (CR55) 2014; 19
Bocchia (CR28) 2018; 8
Çiftçiler, Akın, Erat, Eşkazan (CR65) 2023; 23
Hsieh, Kirschner, Copland (CR38) 2021; 35
Torres-Barrera, Mayani, Chavez-Gonzalez (CR1) 2021; 69
Imagawa (CR22) 2015; 2
Mahon (CR25) 2018; 168
Méndez-Ferrer (CR56) 2020; 20
Ng (CR67) 2014; 123
Roeder (CR47) 2006; 12
Pedersen (CR49) 2023; 41
Kim (CR44) 2022; 32
Stiehl, Ho, Marciniak-Czochra (CR40) 2018; 8
Karg (CR52) 2022; 12
Bartram (CR2) 1983; 306
Krause (CR68) 2013; 19
Shah (CR23) 2020; 61
Becker, Günther, Li, Jolly, Höfer (CR50) 2019; 481
Kalmanti (CR61) 2015; 29
Ohyashiki (CR32) 2012; 157
Legros (CR27) 2017; 123
Le, Andreff, Battula (CR54) 2018; 103
Tang (CR63) 2011; 118
Ureshino (CR64) 2021; 39
Lee (CR30) 2016; 101
Hochhaus (CR10) 2020; 34
Druker (CR7) 2001; 344
Baccarani (CR9) 2013; 122
J Kong (370_CR35) 2021; 100
NP Shah (370_CR23) 2020; 61
C Woywod (370_CR42) 2017; 12
M Brehme (370_CR58) 2016; 6
M Andersen (370_CR39) 2017; 12
A Hochhaus (370_CR10) 2020; 34
NB Becker (370_CR50) 2019; 481
L Kalmanti (370_CR61) 2015; 29
T Holyoake (370_CR4) 2017; 129
E Kim (370_CR44) 2022; 32
F-X Mahon (370_CR17) 2010; 11
M Bocchia (370_CR28) 2018; 8
T Stiehl (370_CR40) 2018; 8
N Takahashi (370_CR29) 2018; 107
JP Radich (370_CR59) 2006; 103
YD Irani (370_CR34) 2020; 191
M Ilander (370_CR33) 2017; 31
AC Fassoni (370_CR41) 2018; 103
PM Le (370_CR54) 2018; 103
KP Ng (370_CR67) 2014; 123
L Legros (370_CR27) 2017; 123
T Hähnel (370_CR53) 2020; 80
S Bernard (370_CR69) 2003; 223
I Roeder (370_CR47) 2006; 12
ChineseMedicalAssociation Chinese Society of Hematology (370_CR57) 2020; 41
M Baccarani (370_CR9) 2013; 122
DM Ross (370_CR15) 2020; 17
K Ohyashiki (370_CR32) 2012; 157
R Hehlmann (370_CR62) 2016; 101
J Imagawa (370_CR22) 2015; 2
T Stiehl (370_CR48) 2020; 80
J Lei (370_CR70) 2020; 492
P Torres-Barrera (370_CR1) 2021; 69
E Karg (370_CR52) 2022; 12
M Tang (370_CR63) 2011; 118
F-X Mahon (370_CR25) 2018; 168
Y-C Hsieh (370_CR38) 2021; 35
CR Bartram (370_CR2) 1983; 306
VR Minciacchi (370_CR26) 2021; 10
G Etienne (370_CR20) 2016; 35
BJ Druker (370_CR5) 2006; 355
DS Krause (370_CR68) 2013; 19
MC Mackey (370_CR71) 2001; 34
R Kurzrock (370_CR3) 1988; 319
F Michor (370_CR46) 2005; 435
A Hochhaus (370_CR12) 2017; 376
RE Clark (370_CR14) 2019; 14
M Molica (370_CR11) 2019; 98
H Kantarjian (370_CR8) 2010; 362
O Benjamini (370_CR31) 2014; 55
S Azizidoost (370_CR55) 2014; 19
B Zhang (370_CR36) 2010; 17
P Ashcroft (370_CR51) 2017; 13
H Kantarjian (370_CR60) 2012; 119
D Duarte (370_CR37) 2018; 131
S Saussele (370_CR18) 2018; 19
C Gambacorti-Passerini (370_CR13) 2011; 103
L Campiotti (370_CR16) 2017; 77
GD Clapp (370_CR72) 2015; 75
DM Ross (370_CR24) 2018; 144
DM Ross (370_CR19) 2013; 122
S Méndez-Ferrer (370_CR56) 2020; 20
RK Pedersen (370_CR49) 2023; 41
S-E Lee (370_CR30) 2016; 101
P Harrington (370_CR6) 2021; 28
AL MacLean (370_CR45) 2014; 111
DM Ross (370_CR21) 2018; 32
BJ Druker (370_CR7) 2001; 344
M Andersen (370_CR43) 2020; 326
H Ureshino (370_CR64) 2021; 39
R Çiftçiler (370_CR65) 2023; 23
DM Ross (370_CR66) 2011; 25
References_xml – volume: 75
  start-page: 4053
  year: 2015
  end-page: 4062
  ident: CR72
  article-title: Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0611
  contributor:
    fullname: Clapp
– volume: 34
  start-page: 71
  year: 2001
  end-page: 83
  ident: CR71
  article-title: Cell kinetic status of haematopoietic stem cells
  publication-title: Cell Prolif.
  doi: 10.1046/j.1365-2184.2001.00195.x
  contributor:
    fullname: Mackey
– volume: 118
  start-page: 1622
  year: 2011
  end-page: 1631
  ident: CR63
  article-title: Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
  publication-title: Blood
  doi: 10.1182/blood-2011-02-339267
  contributor:
    fullname: Tang
– volume: 13
  start-page: e1005803
  year: 2017
  ident: CR51
  article-title: Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1005803
  contributor:
    fullname: Bonhoeffer
– volume: 12
  start-page: 1181
  year: 2006
  ident: CR47
  article-title: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
  publication-title: Nat. Med.
  doi: 10.1038/nm1487
  contributor:
    fullname: Roeder
– volume: 129
  start-page: 1595
  year: 2017
  end-page: 1606
  ident: CR4
  article-title: The chronic myeloid leukemia stem cell: stemming the tide of persistence
  publication-title: Blood
  doi: 10.1182/blood-2016-09-696013
  contributor:
    fullname: Vetrie
– volume: 35
  start-page: 1229
  year: 2021
  end-page: 1242
  ident: CR38
  article-title: Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01238-w
  contributor:
    fullname: Copland
– volume: 144
  start-page: 945
  year: 2018
  end-page: 954
  ident: CR24
  article-title: Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-018-2604-x
  contributor:
    fullname: Ross
– volume: 80
  start-page: 2394
  year: 2020
  end-page: 2406
  ident: CR53
  article-title: Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with CML
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-2175
  contributor:
    fullname: Hähnel
– volume: 103
  start-page: 1825
  year: 2018
  end-page: 1834
  ident: CR41
  article-title: Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
  publication-title: Haematologica
  doi: 10.3324/haematol.2018.194522
  contributor:
    fullname: Glauche
– volume: 344
  start-page: 1031
  year: 2001
  end-page: 1037
  ident: CR7
  article-title: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM200104053441401
  contributor:
    fullname: Druker
– volume: 20
  start-page: 285
  year: 2020
  end-page: 298
  ident: CR56
  article-title: Bone marrow niches in haematological malignancies
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0245-2
  contributor:
    fullname: Méndez-Ferrer
– volume: 223
  start-page: 283
  year: 2003
  end-page: 298
  ident: CR69
  article-title: Oscillations in cyclical neutropenia: new evidence based on mathematical modeling
  publication-title: J. Theor. Biol.
  doi: 10.1016/S0022-5193(03)00090-0
  contributor:
    fullname: Mackey
– volume: 69
  start-page: 103295
  year: 2021
  ident: CR1
  article-title: Understanding the hematopoietic microenvironment in chronic myeloid leukemia: a concise review
  publication-title: Curr. Res. Transl. Med.
  doi: 10.1016/j.retram.2021.103295
  contributor:
    fullname: Chavez-Gonzalez
– volume: 35
  start-page: 298
  year: 2016
  end-page: 305
  ident: CR20
  article-title: Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.68.2914
  contributor:
    fullname: Etienne
– volume: 31
  start-page: 1108
  year: 2017
  end-page: 1116
  ident: CR33
  article-title: Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2016.360
  contributor:
    fullname: Ilander
– volume: 19
  start-page: 1513
  year: 2013
  end-page: 1517
  ident: CR68
  article-title: Differential regulation of myeloid leukemias by the bone marrow microenvironment
  publication-title: Nat. Med.
  doi: 10.1038/nm.3364
  contributor:
    fullname: Krause
– volume: 41
  start-page: 260
  year: 2023
  end-page: 270
  ident: CR49
  article-title: HSC niche dynamics in regeneration, pre-malignancy, and cancer: Insights from mathematical modeling
  publication-title: Stem Cells
  doi: 10.1093/stmcls/sxac079
  contributor:
    fullname: Pedersen
– volume: 8
  year: 2018
  ident: CR40
  article-title: Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-21115-4
  contributor:
    fullname: Marciniak-Czochra
– volume: 191
  start-page: 433
  year: 2020
  end-page: 441
  ident: CR34
  article-title: Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.16718
  contributor:
    fullname: Irani
– volume: 17
  start-page: 493
  year: 2020
  end-page: 503
  ident: CR15
  article-title: Treatment-free remission in patients with chronic myeloid leukaemia
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-020-0367-1
  contributor:
    fullname: Hughes
– volume: 111
  start-page: 3883
  year: 2014
  end-page: 3888
  ident: CR45
  article-title: The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1317072111
  contributor:
    fullname: Stumpf
– volume: 34
  start-page: 966
  year: 2020
  end-page: 984
  ident: CR10
  article-title: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0776-2
  contributor:
    fullname: Hochhaus
– volume: 168
  start-page: 461
  year: 2018
  end-page: 470
  ident: CR25
  article-title: Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study
  publication-title: Ann. Intern Med.
  doi: 10.7326/M17-1094
  contributor:
    fullname: Mahon
– volume: 32
  start-page: 100817
  year: 2022
  ident: CR44
  article-title: Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2022.100817
  contributor:
    fullname: Kim
– volume: 25
  start-page: 193
  year: 2011
  end-page: 200
  ident: CR66
  article-title: Do we have to kill the last CML cell?
  publication-title: Leukemia
  doi: 10.1038/leu.2010.197
  contributor:
    fullname: Melo
– volume: 319
  start-page: 990
  year: 1988
  end-page: 998
  ident: CR3
  article-title: The molecular genetics of Philadelphia chromosome–positive leukemias
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198810133191506
  contributor:
    fullname: Talpaz
– volume: 77
  start-page: 48
  year: 2017
  end-page: 56
  ident: CR16
  article-title: Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.02.028
  contributor:
    fullname: Campiotti
– volume: 17
  start-page: 427
  year: 2010
  end-page: 442
  ident: CR36
  article-title: Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.03.011
  contributor:
    fullname: Zhang
– volume: 103
  start-page: 1945
  year: 2018
  end-page: 1955
  ident: CR54
  article-title: Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis
  publication-title: Haematologica
  doi: 10.3324/haematol.2018.197004
  contributor:
    fullname: Battula
– volume: 131
  start-page: 1507
  year: 2018
  end-page: 1511
  ident: CR37
  article-title: The interplay of leukemia cells and the bone marrow microenvironment
  publication-title: Blood
  doi: 10.1182/blood-2017-12-784132
  contributor:
    fullname: Lo Celso
– volume: 29
  start-page: 1123
  year: 2015
  end-page: 1132
  ident: CR61
  article-title: Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
  publication-title: Leukemia
  doi: 10.1038/leu.2015.36
  contributor:
    fullname: Kalmanti
– volume: 123
  start-page: 3316
  year: 2014
  end-page: 3326
  ident: CR67
  article-title: Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition
  publication-title: Myeloid Neoplasia
  contributor:
    fullname: Ng
– volume: 23
  start-page: 8
  year: 2023
  end-page: 14
  ident: CR65
  article-title: A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): can it be applied in clinical practice?
  publication-title: Clin. Lymphoma Myeloma Leuk.
  doi: 10.1016/j.clml.2022.09.004
  contributor:
    fullname: Eşkazan
– volume: 12
  start-page: 1028871
  year: 2022
  ident: CR52
  article-title: Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1028871
  contributor:
    fullname: Karg
– volume: 14
  start-page: 507
  year: 2019
  end-page: 514
  ident: CR14
  article-title: Tyrosine kinase inhibitor therapy discontinuation for patients with chronic myeloid leukaemia in clinical practice
  publication-title: Curr. Hematol. Malignancy Rep.
  doi: 10.1007/s11899-019-00548-2
  contributor:
    fullname: Clark
– volume: 122
  start-page: 515
  year: 2013
  end-page: 522
  ident: CR19
  article-title: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
  publication-title: Blood
  doi: 10.1182/blood-2013-02-483750
  contributor:
    fullname: Ross
– volume: 119
  start-page: 1981
  year: 2012
  end-page: 1987
  ident: CR60
  article-title: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
  publication-title: Blood
  doi: 10.1182/blood-2011-08-358135
  contributor:
    fullname: Kantarjian
– volume: 19
  start-page: 232
  year: 2014
  end-page: 238
  ident: CR55
  article-title: Bone marrow neoplastic niche in leukemia
  publication-title: Hematology
  doi: 10.1179/1607845413Y.0000000111
  contributor:
    fullname: Saki
– volume: 123
  start-page: 4403
  year: 2017
  end-page: 4410
  ident: CR27
  article-title: Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia
  publication-title: Cancer
  doi: 10.1002/cncr.30885
  contributor:
    fullname: Legros
– volume: 100
  start-page: 2557
  year: 2021
  end-page: 2566
  ident: CR35
  article-title: Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment
  publication-title: Ann. Hematol.
  doi: 10.1007/s00277-021-04606-9
  contributor:
    fullname: Kong
– volume: 39
  start-page: 549
  year: 2021
  end-page: 557
  ident: CR64
  article-title: Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience
  publication-title: Hematol. Oncol.
  doi: 10.1002/hon.2896
  contributor:
    fullname: Ureshino
– volume: 492
  start-page: 110196
  year: 2020
  ident: CR70
  article-title: A general mathematical framework for understanding the behavior of heterogeneous stem cell regeneration
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2020.110196
  contributor:
    fullname: Lei
– volume: 80
  start-page: 3983
  year: 2020
  end-page: 3992
  ident: CR48
  article-title: Mathematical modeling provides evidence for niche competition in human AML and serves as a tool to improve risk stratification
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-0283
  contributor:
    fullname: Marciniak-Czochra
– volume: 8
  start-page: 194
  year: 2018
  ident: CR28
  article-title: Residual peripheral blood CD26 leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2018.00194
  contributor:
    fullname: Bocchia
– volume: 122
  start-page: 872
  year: 2013
  end-page: 884
  ident: CR9
  article-title: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
  publication-title: Blood
  doi: 10.1182/blood-2013-05-501569
  contributor:
    fullname: Baccarani
– volume: 101
  start-page: 657
  year: 2016
  end-page: 659
  ident: CR62
  article-title: Innovation in hematology. Perspectives: CML 2016
  publication-title: Haematologica
  doi: 10.3324/haematol.2016.142877
  contributor:
    fullname: Hehlmann
– volume: 98
  start-page: 1891
  year: 2019
  end-page: 1904
  ident: CR11
  article-title: Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
  publication-title: Ann. Hematol.
  doi: 10.1007/s00277-019-03706-x
  contributor:
    fullname: Molica
– volume: 362
  start-page: 2260
  year: 2010
  end-page: 2270
  ident: CR8
  article-title: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1002315
  contributor:
    fullname: Kantarjian
– volume: 103
  start-page: 553
  year: 2011
  end-page: 561
  ident: CR13
  article-title: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
  publication-title: JNCI: J. Natl Cancer Institute
  doi: 10.1093/jnci/djr060
  contributor:
    fullname: Gambacorti-Passerini
– volume: 19
  start-page: 747
  year: 2018
  end-page: 757
  ident: CR18
  article-title: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecific interim analysis of a prospective, multicentre, non-randomised, trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30192-X
  contributor:
    fullname: Saussele
– volume: 41
  start-page: 353
  year: 2020
  end-page: 364
  ident: CR57
  article-title: The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)
  publication-title: Chin. J. Hematol.
  contributor:
    fullname: Chinese Society of Hematology
– volume: 355
  start-page: 2408
  year: 2006
  end-page: 2417
  ident: CR5
  article-title: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa062867
  contributor:
    fullname: Druker
– volume: 11
  start-page: 1029
  year: 2010
  end-page: 1035
  ident: CR17
  article-title: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentra Stop Imatinib (STIM) trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(10)70233-3
  contributor:
    fullname: Mahon
– volume: 2
  start-page: e528
  year: 2015
  end-page: 35
  ident: CR22
  article-title: Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (dadi trial): a multicentre phase 2 trial
  publication-title: Lancet Haematol.
  doi: 10.1016/S2352-3026(15)00196-9
  contributor:
    fullname: Imagawa
– volume: 61
  start-page: 650
  year: 2020
  end-page: 659
  ident: CR23
  article-title: Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
  publication-title: Leuk. Lymphoma
  doi: 10.1080/10428194.2019.1675879
  contributor:
    fullname: Shah
– volume: 28
  start-page: 122
  year: 2021
  end-page: 127
  ident: CR6
  article-title: Novel developments in chronic myeloid leukaemia
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/MOH.0000000000000630
  contributor:
    fullname: Lavallade
– volume: 32
  start-page: 2572
  year: 2018
  end-page: 2579
  ident: CR21
  article-title: Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0264-0
  contributor:
    fullname: Ross
– volume: 12
  start-page: e0183620
  year: 2017
  ident: CR39
  article-title: Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0183620
  contributor:
    fullname: Andersen
– volume: 435
  start-page: 1267
  year: 2005
  ident: CR46
  article-title: Dynamics of chronic myeloid leukaemia
  publication-title: Nature
  doi: 10.1038/nature03669
  contributor:
    fullname: Michor
– volume: 157
  start-page: 254
  year: 2012
  end-page: 256
  ident: CR32
  article-title: Increased natural killer cells and decreased CD3 CD8 CD62L T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2011.08939.x
  contributor:
    fullname: Ohyashiki
– volume: 103
  start-page: 2794 – 2799
  year: 2006
  ident: CR59
  article-title: Gene expression changes associated with progression and response in chronic myeloid leukemia
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0510423103
  contributor:
    fullname: Radich
– volume: 6
  year: 2016
  ident: CR58
  article-title: Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia
  publication-title: Sci. Rep.
  doi: 10.1038/srep24057
  contributor:
    fullname: Brehme
– volume: 376
  start-page: 917
  year: 2017
  end-page: 927
  ident: CR12
  article-title: Long-term outcomes of imatinib treatment for chronic myeloid leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1609324
  contributor:
    fullname: Hochhaus
– volume: 306
  start-page: 277
  year: 1983
  ident: CR2
  article-title: Translocation of oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
  publication-title: Nature
  doi: 10.1038/306277a0
  contributor:
    fullname: Bartram
– volume: 107
  start-page: 185
  year: 2018
  end-page: 193
  ident: CR29
  article-title: Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
  publication-title: Int. J. Hematol.
  doi: 10.1007/s12185-017-2334-x
  contributor:
    fullname: Takahashi
– volume: 481
  start-page: 100
  year: 2019
  end-page: 109
  ident: CR50
  article-title: Stem cell homeostasis by integral feedback through the niche
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2018.12.029
  contributor:
    fullname: Höfer
– volume: 55
  start-page: 2879
  year: 2014
  end-page: 2886
  ident: CR31
  article-title: Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
  publication-title: Leuk. Lymphoma
  doi: 10.3109/10428194.2013.831092
  contributor:
    fullname: Benjamini
– volume: 10
  start-page: 117
  year: 2021
  ident: CR26
  article-title: Chronic myeloid leukemia: a model disease of the past, present and future
  publication-title: Cells
  doi: 10.3390/cells10010117
  contributor:
    fullname: Krause
– volume: 12
  start-page: e0179700
  year: 2017
  ident: CR42
  article-title: Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: response to dasatinib or nilotinib therapy
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0179700
  contributor:
    fullname: Fla
– volume: 101
  start-page: 717
  year: 2016
  end-page: 723
  ident: CR30
  article-title: Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the kid study
  publication-title: Haematologica
  doi: 10.3324/haematol.2015.139899
  contributor:
    fullname: Lee
– volume: 326
  start-page: 108372
  year: 2020
  ident: CR43
  article-title: Global dynamics of healthy and cancer cells competing in the hematopoietic system
  publication-title: Math. Biosci.
  doi: 10.1016/j.mbs.2020.108372
  contributor:
    fullname: Ottesen
– volume: 481
  start-page: 100
  year: 2019
  ident: 370_CR50
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2018.12.029
  contributor:
    fullname: NB Becker
– volume: 131
  start-page: 1507
  year: 2018
  ident: 370_CR37
  publication-title: Blood
  doi: 10.1182/blood-2017-12-784132
  contributor:
    fullname: D Duarte
– volume: 35
  start-page: 298
  year: 2016
  ident: 370_CR20
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.68.2914
  contributor:
    fullname: G Etienne
– volume: 13
  start-page: e1005803
  year: 2017
  ident: 370_CR51
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1005803
  contributor:
    fullname: P Ashcroft
– volume: 98
  start-page: 1891
  year: 2019
  ident: 370_CR11
  publication-title: Ann. Hematol.
  doi: 10.1007/s00277-019-03706-x
  contributor:
    fullname: M Molica
– volume: 376
  start-page: 917
  year: 2017
  ident: 370_CR12
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1609324
  contributor:
    fullname: A Hochhaus
– volume: 8
  start-page: 194
  year: 2018
  ident: 370_CR28
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2018.00194
  contributor:
    fullname: M Bocchia
– volume: 107
  start-page: 185
  year: 2018
  ident: 370_CR29
  publication-title: Int. J. Hematol.
  doi: 10.1007/s12185-017-2334-x
  contributor:
    fullname: N Takahashi
– volume: 191
  start-page: 433
  year: 2020
  ident: 370_CR34
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.16718
  contributor:
    fullname: YD Irani
– volume: 77
  start-page: 48
  year: 2017
  ident: 370_CR16
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.02.028
  contributor:
    fullname: L Campiotti
– volume: 326
  start-page: 108372
  year: 2020
  ident: 370_CR43
  publication-title: Math. Biosci.
  doi: 10.1016/j.mbs.2020.108372
  contributor:
    fullname: M Andersen
– volume: 28
  start-page: 122
  year: 2021
  ident: 370_CR6
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/MOH.0000000000000630
  contributor:
    fullname: P Harrington
– volume: 61
  start-page: 650
  year: 2020
  ident: 370_CR23
  publication-title: Leuk. Lymphoma
  doi: 10.1080/10428194.2019.1675879
  contributor:
    fullname: NP Shah
– volume: 34
  start-page: 71
  year: 2001
  ident: 370_CR71
  publication-title: Cell Prolif.
  doi: 10.1046/j.1365-2184.2001.00195.x
  contributor:
    fullname: MC Mackey
– volume: 17
  start-page: 493
  year: 2020
  ident: 370_CR15
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-020-0367-1
  contributor:
    fullname: DM Ross
– volume: 80
  start-page: 3983
  year: 2020
  ident: 370_CR48
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-0283
  contributor:
    fullname: T Stiehl
– volume: 32
  start-page: 2572
  year: 2018
  ident: 370_CR21
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0264-0
  contributor:
    fullname: DM Ross
– volume: 362
  start-page: 2260
  year: 2010
  ident: 370_CR8
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1002315
  contributor:
    fullname: H Kantarjian
– volume: 355
  start-page: 2408
  year: 2006
  ident: 370_CR5
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa062867
  contributor:
    fullname: BJ Druker
– volume: 17
  start-page: 427
  year: 2010
  ident: 370_CR36
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.03.011
  contributor:
    fullname: B Zhang
– volume: 101
  start-page: 717
  year: 2016
  ident: 370_CR30
  publication-title: Haematologica
  doi: 10.3324/haematol.2015.139899
  contributor:
    fullname: S-E Lee
– volume: 122
  start-page: 515
  year: 2013
  ident: 370_CR19
  publication-title: Blood
  doi: 10.1182/blood-2013-02-483750
  contributor:
    fullname: DM Ross
– volume: 34
  start-page: 966
  year: 2020
  ident: 370_CR10
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0776-2
  contributor:
    fullname: A Hochhaus
– volume: 6
  year: 2016
  ident: 370_CR58
  publication-title: Sci. Rep.
  doi: 10.1038/srep24057
  contributor:
    fullname: M Brehme
– volume: 103
  start-page: 553
  year: 2011
  ident: 370_CR13
  publication-title: JNCI: J. Natl Cancer Institute
  doi: 10.1093/jnci/djr060
  contributor:
    fullname: C Gambacorti-Passerini
– volume: 144
  start-page: 945
  year: 2018
  ident: 370_CR24
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-018-2604-x
  contributor:
    fullname: DM Ross
– volume: 35
  start-page: 1229
  year: 2021
  ident: 370_CR38
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01238-w
  contributor:
    fullname: Y-C Hsieh
– volume: 14
  start-page: 507
  year: 2019
  ident: 370_CR14
  publication-title: Curr. Hematol. Malignancy Rep.
  doi: 10.1007/s11899-019-00548-2
  contributor:
    fullname: RE Clark
– volume: 11
  start-page: 1029
  year: 2010
  ident: 370_CR17
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(10)70233-3
  contributor:
    fullname: F-X Mahon
– volume: 122
  start-page: 872
  year: 2013
  ident: 370_CR9
  publication-title: Blood
  doi: 10.1182/blood-2013-05-501569
  contributor:
    fullname: M Baccarani
– volume: 119
  start-page: 1981
  year: 2012
  ident: 370_CR60
  publication-title: Blood
  doi: 10.1182/blood-2011-08-358135
  contributor:
    fullname: H Kantarjian
– volume: 12
  start-page: 1181
  year: 2006
  ident: 370_CR47
  publication-title: Nat. Med.
  doi: 10.1038/nm1487
  contributor:
    fullname: I Roeder
– volume: 80
  start-page: 2394
  year: 2020
  ident: 370_CR53
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-2175
  contributor:
    fullname: T Hähnel
– volume: 435
  start-page: 1267
  year: 2005
  ident: 370_CR46
  publication-title: Nature
  doi: 10.1038/nature03669
  contributor:
    fullname: F Michor
– volume: 25
  start-page: 193
  year: 2011
  ident: 370_CR66
  publication-title: Leukemia
  doi: 10.1038/leu.2010.197
  contributor:
    fullname: DM Ross
– volume: 123
  start-page: 4403
  year: 2017
  ident: 370_CR27
  publication-title: Cancer
  doi: 10.1002/cncr.30885
  contributor:
    fullname: L Legros
– volume: 129
  start-page: 1595
  year: 2017
  ident: 370_CR4
  publication-title: Blood
  doi: 10.1182/blood-2016-09-696013
  contributor:
    fullname: T Holyoake
– volume: 41
  start-page: 353
  year: 2020
  ident: 370_CR57
  publication-title: Chin. J. Hematol.
  contributor:
    fullname: ChineseMedicalAssociation Chinese Society of Hematology
– volume: 19
  start-page: 747
  year: 2018
  ident: 370_CR18
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30192-X
  contributor:
    fullname: S Saussele
– volume: 12
  start-page: e0179700
  year: 2017
  ident: 370_CR42
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0179700
  contributor:
    fullname: C Woywod
– volume: 101
  start-page: 657
  year: 2016
  ident: 370_CR62
  publication-title: Haematologica
  doi: 10.3324/haematol.2016.142877
  contributor:
    fullname: R Hehlmann
– volume: 344
  start-page: 1031
  year: 2001
  ident: 370_CR7
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM200104053441401
  contributor:
    fullname: BJ Druker
– volume: 19
  start-page: 1513
  year: 2013
  ident: 370_CR68
  publication-title: Nat. Med.
  doi: 10.1038/nm.3364
  contributor:
    fullname: DS Krause
– volume: 10
  start-page: 117
  year: 2021
  ident: 370_CR26
  publication-title: Cells
  doi: 10.3390/cells10010117
  contributor:
    fullname: VR Minciacchi
– volume: 157
  start-page: 254
  year: 2012
  ident: 370_CR32
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2011.08939.x
  contributor:
    fullname: K Ohyashiki
– volume: 103
  start-page: 1945
  year: 2018
  ident: 370_CR54
  publication-title: Haematologica
  doi: 10.3324/haematol.2018.197004
  contributor:
    fullname: PM Le
– volume: 55
  start-page: 2879
  year: 2014
  ident: 370_CR31
  publication-title: Leuk. Lymphoma
  doi: 10.3109/10428194.2013.831092
  contributor:
    fullname: O Benjamini
– volume: 20
  start-page: 285
  year: 2020
  ident: 370_CR56
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0245-2
  contributor:
    fullname: S Méndez-Ferrer
– volume: 100
  start-page: 2557
  year: 2021
  ident: 370_CR35
  publication-title: Ann. Hematol.
  doi: 10.1007/s00277-021-04606-9
  contributor:
    fullname: J Kong
– volume: 2
  start-page: e528
  year: 2015
  ident: 370_CR22
  publication-title: Lancet Haematol.
  doi: 10.1016/S2352-3026(15)00196-9
  contributor:
    fullname: J Imagawa
– volume: 492
  start-page: 110196
  year: 2020
  ident: 370_CR70
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2020.110196
  contributor:
    fullname: J Lei
– volume: 31
  start-page: 1108
  year: 2017
  ident: 370_CR33
  publication-title: Leukemia
  doi: 10.1038/leu.2016.360
  contributor:
    fullname: M Ilander
– volume: 75
  start-page: 4053
  year: 2015
  ident: 370_CR72
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0611
  contributor:
    fullname: GD Clapp
– volume: 29
  start-page: 1123
  year: 2015
  ident: 370_CR61
  publication-title: Leukemia
  doi: 10.1038/leu.2015.36
  contributor:
    fullname: L Kalmanti
– volume: 103
  start-page: 2794 – 2799
  year: 2006
  ident: 370_CR59
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0510423103
  contributor:
    fullname: JP Radich
– volume: 168
  start-page: 461
  year: 2018
  ident: 370_CR25
  publication-title: Ann. Intern Med.
  doi: 10.7326/M17-1094
  contributor:
    fullname: F-X Mahon
– volume: 39
  start-page: 549
  year: 2021
  ident: 370_CR64
  publication-title: Hematol. Oncol.
  doi: 10.1002/hon.2896
  contributor:
    fullname: H Ureshino
– volume: 32
  start-page: 100817
  year: 2022
  ident: 370_CR44
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2022.100817
  contributor:
    fullname: E Kim
– volume: 118
  start-page: 1622
  year: 2011
  ident: 370_CR63
  publication-title: Blood
  doi: 10.1182/blood-2011-02-339267
  contributor:
    fullname: M Tang
– volume: 8
  year: 2018
  ident: 370_CR40
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-21115-4
  contributor:
    fullname: T Stiehl
– volume: 306
  start-page: 277
  year: 1983
  ident: 370_CR2
  publication-title: Nature
  doi: 10.1038/306277a0
  contributor:
    fullname: CR Bartram
– volume: 69
  start-page: 103295
  year: 2021
  ident: 370_CR1
  publication-title: Curr. Res. Transl. Med.
  doi: 10.1016/j.retram.2021.103295
  contributor:
    fullname: P Torres-Barrera
– volume: 319
  start-page: 990
  year: 1988
  ident: 370_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198810133191506
  contributor:
    fullname: R Kurzrock
– volume: 123
  start-page: 3316
  year: 2014
  ident: 370_CR67
  publication-title: Myeloid Neoplasia
  contributor:
    fullname: KP Ng
– volume: 103
  start-page: 1825
  year: 2018
  ident: 370_CR41
  publication-title: Haematologica
  doi: 10.3324/haematol.2018.194522
  contributor:
    fullname: AC Fassoni
– volume: 12
  start-page: 1028871
  year: 2022
  ident: 370_CR52
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1028871
  contributor:
    fullname: E Karg
– volume: 223
  start-page: 283
  year: 2003
  ident: 370_CR69
  publication-title: J. Theor. Biol.
  doi: 10.1016/S0022-5193(03)00090-0
  contributor:
    fullname: S Bernard
– volume: 111
  start-page: 3883
  year: 2014
  ident: 370_CR45
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1317072111
  contributor:
    fullname: AL MacLean
– volume: 41
  start-page: 260
  year: 2023
  ident: 370_CR49
  publication-title: Stem Cells
  doi: 10.1093/stmcls/sxac079
  contributor:
    fullname: RK Pedersen
– volume: 12
  start-page: e0183620
  year: 2017
  ident: 370_CR39
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0183620
  contributor:
    fullname: M Andersen
– volume: 19
  start-page: 232
  year: 2014
  ident: 370_CR55
  publication-title: Hematology
  doi: 10.1179/1607845413Y.0000000111
  contributor:
    fullname: S Azizidoost
– volume: 23
  start-page: 8
  year: 2023
  ident: 370_CR65
  publication-title: Clin. Lymphoma Myeloma Leuk.
  doi: 10.1016/j.clml.2022.09.004
  contributor:
    fullname: R Çiftçiler
SSID ssj0001634210
Score 2.3083458
Snippet Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR) upon...
Abstract Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR)...
Abstract Patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitors (TKIs) have been known to achieve treatment-free remission (TFR)...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 45
SubjectTerms 639/705/1041
692/699/67
Bioinformatics
Biomedical and Life Sciences
Bone marrow
Chronic myeloid leukemia
Computational Biology/Bioinformatics
Computer Appl. in Life Sciences
Computer Simulation
Feedback
Humans
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Life Sciences
Mathematical models
Models, Biological
Myeloid leukemia
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - metabolism
Patients
Peripheral blood
Protein Kinase Inhibitors - therapeutic use
Remission
Remission (Medicine)
Remission Induction
Stem cells
Systems Biology
Tumor microenvironment
Tumor Microenvironment - drug effects
Tumors
Tyrosine kinase inhibitors
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEC5kQfAivu11lQjeNGw6ST9yVHFZBD25sLeQRwUH155lZuew_95K0jPu-MCLx05CE6oqqa-SylcAr0wvMfOucXLFjmsjEjdOeO5UatuQkCB-fuD86XN_eqY_nnfnN0p95ZywSg9cBXfsnYipTw6DQO3C6OTooqB4cNQ-UWxXdt-2uxFMldOVXmkKZuZXMkKNx2vyVDmTUWqeOVcE13ueqBD2_wll_p4s-cuNaXFEJ_fg7owg2ds68_twC6cHcLvWlLx-CJe1TsN8xsdKpRv6D8tUTWRqjBYtm4vssLha5PMEtss252mFSENJ-fkUjS0mFip7Lvt-jRfLRWQXuPlG_Y7NjKzrR3B28uHL-1M-l1XgQefsS-XiQCioG6PykVqUxx6NHIYefQpRS68NffeDSTK5QXUeo-kpMnKDlEMK6jEcTMsJnwJzPpqoXKcSoRITWh8JsKNBIQIhJYcNvN6K2F5W9gxbbr3VaKtCLCnEFoVY3cC7rIXdyMx8XRrIHuxsD_Zf9tDA0VaHdl6Oa5vvFjWB165v4OWum2SZb0fchMtNHWPIYoVo4ElV-W4maiSfTvtxA-OeMexNdb9nWnwtZN1trkBKm2QDb7Z283Nef5fF4f-QxTO4I4vBay6HIzi4Wm3wOWGoK_-iLJcfJBsc-g
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BKyQuiDeBgozEDaw6tvPwCVHUqkKiQohKvUV-jGFFSZbd7qH_nnHi3dXyOia2Iscz9nyeGX8D8MrUEhPvGidTbLk2InJjheNWxbL0EQnipwvOH8_q03P94aK6yA63ZU6rXO-J40YdBp985IcpPKQJf1T12_lPnqpGpehqLqFxE_ZlqVOYdv_o-OzT562XpVaaDjX5toxQ7eGSLFbKaJSaJ-4VwfWORRqJ-_-GNv9MmvwtcjoapJO7cCcjSfZuEv09uIH9fbg11Za8fgDzqV5D9vWxseINfYclyiZSOUaLl-ViOywsZsmvwDZZ5zwuEKkrKUHyprFZz_zEost-XOPlMAvsElffqd2yzMy6fAjnJ8df3p_yXF6Be52yMJUNDaGhqg3KBXqjHNZoZNPU6KIPWjpt6LluTJTRNqpyGExNJyTbSNlErx7BXj_0-ASYdcEEZSsVCZ0YX7pAwB0NCuEJMVks4PV6irv5xKLRjdFv1XaTQDoSSDcKpNMFHCUpbHomBuzxxbD42uUFRUZehFhHi16gtr61srVBoCNz6yKd-Qs4WMuwy8ty2W2VqICXm2aayxQlsT0Oq6mPIc0VooDHk8g3I1Et2Xbalwtod5RhZ6i7Lf3s20jaXaZKpLRZFvBmrTfbcf17Lp7-_zeewW05qrLmsjmAvavFCp8TSrpyL_JS-AW4IBOS
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BERIXVN6hBRmJG1g4tuPER1hRVUhwolJvkR9jsaJkq93uof-esZPdKlAOHGM7keWZyXz2jL8BeGuNxMy7xskVO66tSNw64blTqa5DQoL4-YLz12_m9Ex_OW_OJ5qcfBdmFr9X3YcNOZicgCg1z1Qpguu7cK-pjcgavDCLm_MUozRtX6Z7Mbe_OvM9haL_Nlz5d3rkHzHS4npODuHhhBnZx1HIj-AODo_h_lhF8voJXI6VGaZTPVZq29B3WCZnIuViZKZsKqvD4nqZTxDYPr-cpzUiDSVx53MzthxYGPly2a9rvFgtI7vA7U_qd2ziYN08hbOTz98Xp3wqpMCDzvmWysWWcE_TReUjtSiPBq1sW4M-hail15aeTWuTTK5VjcdoDe2FXCtlm4J6BgfDasAXwJyPNirXqEQ4xIbaR4LoaFGIQNjIYQXvdkvcX458GX2Jc6uuHwXSk0D6IpBeV_ApS2E_MnNdlwZSgX4yHXLnIiaTHAaB2oXOyc5FgZ4cq0-0u6_geCfDfjLATZ-jiZrgamMqeLPvprXM8RA34Go7jrGko0JU8HwU-X4mqiMvTn_gCrqZMsymOu8Zlj8KPXeda47Sb7GC9zu9uZnXv9fi5f8NP4IHsqi25rI9hoOr9RZfET668q-LYfwGIkcK-Q
  priority: 102
  providerName: Springer Nature
Title Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients
URI https://link.springer.com/article/10.1038/s41540-024-00370-4
https://www.ncbi.nlm.nih.gov/pubmed/38678088
https://www.proquest.com/docview/3047404556
https://search.proquest.com/docview/3047943500
https://pubmed.ncbi.nlm.nih.gov/PMC11055880
https://doaj.org/article/ba0df6faec0e4ac8a28ad0eb284bf469
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_ajsFexr7nrQsa7G1zo1iybD2moaUEWsq2Qt6MPlezxAlJ89D_fifZzpZ9vOwpWBKO0J18vzudfgfwQYrMBd61FE2xSrmkPpWK6lQxPxoZ7xDihwvOl1fi4oZPZ_nsAER_FyYm7RtdnzTzxUlT38bcytXCDPs8seH15WQUqjqi4g0P4bBg7BcfPUZWBOPoyHQ3ZCgrhxu0UiGLMeNp4FuhKd-zQpGs_28I889Eyd9OS6MROn8Cjzv0SMbtLJ_CgWuewcO2nuT9c1i1NRq6-B6JVW7wPSTQNKGaEdywpCuwQ-y6DrEEsss0T_3aORyKgg8RNFI3xLTMuWRx7-bL2pK5237HfkU6NtbNC7g5P_s6uUi7kgqp4SHzkilbIALKS8u0xRamnXAyKwrhtDeWZ5pLfBaF9JlXBcu1s1KgV6SKLCu8YS_hqFk27jUQpa20TOXMIyKRZqQtgnUnHaUGUZJyCXzsl7hatcwZVTzxZmXVCqRCgVRRIBVP4DRIYTcysF7HhuX6W9XJHg07tV545Qx1XJlSZaWy1Gk0sdqjn5_AcS_DqtuKmyqcK3IErrlI4P2uG9cynIyoxi237RiJ2kppAq9ake9mwkq05_gtTqDcU4a9qe73oN5Gou5eTxP41OvNz3n9ey3e_P8_vYVHWVRznmbFMRzdrbfuHaKmOz3ArTIrBvBgPJ5-meLv6dnV9WdsnYjJIEYiBnEb_QCL8B-2
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,27955,27956,31752,31753,33777,33778,41153,42222,43343,43838,51609,53825,53827,74100,74657
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxEB5BKkQviHcXChiJG1h1bO_DJ0RRqwBthFAr9Wb5CRFlE5Lm0H_PeNdJFF7HXVsrr2fs-Twz_gbglap4SLxrFE2xoVKxSJVhlhoRh0MXA0L8dMH5dFyNzuXHi_IiO9wWOa1ytSd2G7WfuuQjP0jhIYn4o6zezn7SVDUqRVdzCY2bsJMoN5sB7BwejT9_2XhZKiHxUJNvyzDRHCzQYqWMRi5p4l5hVG5ZpI64_29o88-kyd8ip51BOr4LdzKSJO960d-DG6G9D7f62pLXD2DW12vIvj7SVbzB75BE2YQqR3Dxklxsh_j5JPkVyDrrnMZ5CNgVlSB508ikJa5n0SU_rsPldOLJZVh-x3ZDMjPr4iGcHx-dvR_RXF6BOpmyMIXxNaKhsvHCenwjbKiC4nVdBRudl9xKhc9VrSKPphalDV5VeEIyNed1dOIRDNppG_aAGOuVF6YUEdGJckPrEbgHFRhziJhMKOD1aor1rGfR0F30WzS6F4hGgehOIFoWcJiksO6ZGLC7F9P5V50XFBp55mMVTXAsSOMawxvjWbBobm3EM38B-ysZ6rwsF3qjRAW8XDfjXKYoiWnDdNn3Uai5jBXwuBf5eiSiQduO-3IBzZYybA11u6WdfOtIu4epEilulgW8WenNZlz_nosn__-NF3B7dHZ6ok8-jD89hV3eqbWkvN6HwdV8GZ4hYrqyz_Oy-AXnrRaI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgEYgL4k1gASNxA6uu7cbxCfGqlteKAyv1ZtnxGCqWpLTbw_57xo7bqryOja3I9cx4Ps9M5iPkqakFpL5rDF2xY8rwyIzjnjkZx-M2AkL89IHzp-P66ES9n01mpf5pVcoqN2diPqhD36YY-SilhxTij0k9iqUs4vOb6YvFT5YYpFKmtdBpXCSX0EvyROOgZ3oXb6mlwutN-W6Gy2a0Qt-VahuFYqkLC2dqzzflFv5_w51_lk_-lkPNrml6nVwrmJK-HJTgBrkA3U1yeWCZPL9FFgNzQ4n60cx9g--hqXkTKh9FM6aFdoeG5TxFGOi2_pzFJQBORXVIcTU672g79NOlP87htJ8Hegrr7zjuaOnRurpNTqZvv7w-YoVogbUq1WNKFzTiokkTpA_4RHqowQita_CxDUp4ZfB3rU0U0Wk58RBMjXclp4XQsZV3yEHXd3CPUOeDCdJNZEScYtqxDwjhwQDnLWInBxV5ttliuxj6adicB5eNHQRiUSA2C8SqirxKUtjOTL2w84N--dUW00J3z0Oso4OWg3Jt40TjAgePjtdHvP1X5HAjQ1sMdGV36lSRJ9th3MuUL3Ed9OthjkEd5rwidweRb1ciG_TyeEJXpNlThr2l7o9082-5ffc4cZLisVmR5xu92a3r33tx__9_4zG5gvZgP747_vCAXBVZqxUT-pAcnC3X8BCh05l_lG3iFwJ_GUU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Computational+modeling+reveals+key+factors+driving+treatment-free+remission+in+chronic+myeloid+leukemia+patients&rft.jtitle=NPJ+systems+biology+and+applications&rft.au=Lai%2C+Xiulan&rft.au=Jiao%2C+Xiaopei&rft.au=Zhang%2C+Haojian&rft.au=Lei%2C+Jinzhi&rft.date=2024-04-27&rft.issn=2056-7189&rft.eissn=2056-7189&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1038%2Fs41540-024-00370-4&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41540_024_00370_4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-7189&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-7189&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-7189&client=summon